Advanced ovarian cancer treated in pregnancy and detected by cell-free DNA aneuploidy screening

Christina N Cordeiro Mitchell; Tricia Murdock; Amanda N Fader; Rebecca L Stone

doi:10.1016/j.gore.2018.03.006

Advanced ovarian cancer treated in pregnancy and detected by cell-free DNA aneuploidy screening

Gynecol Oncol Rep. 2018 Mar 23:24:48-50. doi: 10.1016/j.gore.2018.03.006. eCollection 2018 May.

Authors

Christina N Cordeiro Mitchell¹, Tricia Murdock², Amanda N Fader³, Rebecca L Stone³

Affiliations

¹ Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

•Abnormal cell free DNA results may indicate occult maternal malignancy.•Cesarean-cytoreductive surgery is feasible even with significant disease burden.•Carboplatin/paclitaxel is first line for epithelial ovarian cancer in pregnancy.

Keywords: Cancer in pregnancy; Cell free DNA screening; Chemotherapy in pregnancy; Fetal aneuploidy screening; Noninvasive prenatal testing; Ovarian cancer.

Publication types

Case Reports